Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$650.06 USD

650.06
798,784

+25.87 (4.14%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $650.31 +0.25 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Humana Extends Value-based Care Services in North Carolina

by Zacks Equity Research

Humana (HUM) strengthens ties with Aledade to expand value-based care services for its Medicare Advantage members in North Carolina.

Zacks Equity Research

Teladoc (TDOC) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Teladoc's (TDOC) Q4 results reflect strong revenue growth, partially offset by high expenses.

Zacks Equity Research

Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Nevro (NVRO) sees strong segmental contributions in Q4.

Zacks Equity Research

Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

Inogen (INGN) sees segmental softness in the fourth quarter.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

Zacks Equity Research

Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.

Zacks Equity Research

HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

HMS Holdings' (HMSY) fourth-quarter earnings benefit from higher revenues at Analytical Services unit and strong 2020 outlook.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

Zacks Equity Research

Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.

Zacks Equity Research

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

by Zacks Equity Research

Masimo (MASI) sees expansion in gross and operating margin in Q4.

Zacks Equity Research

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.

Zacks Equity Research

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.

Zacks Equity Research

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

Zacks Equity Research

Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

by Zacks Equity Research

DaVita (DVA) gains from dialysis services in the United States in Q4.

Zacks Equity Research

Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Zacks Equity Research

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

Zacks Equity Research

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Zacks Equity Research

Here's Why You Should Retain IDEXX Laboratories Stock Now

by Zacks Equity Research

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

by Zacks Equity Research

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

Zacks Equity Research

Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?